Sign In
Buy HRMY
$35.24
-0.620 (-1.73%)
At Close: Jul 31, 2026
Harmony Biosciences Holdings, Inc. (HRMY) CEO John Jacobs on Q2 2022 Results - Earnings Call Transcript
11:07am, Tuesday, 02'nd Aug 2022
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q2 2022 Earnings Conference Call August 2, 2022 8:30 AM ET Company Participants Luis Sanay - Head, IR John Jacobs - President and CEO Jeffrey Dierks -
Harmony Biosciences Makes Leap Out Of Buy Zone After Narcolepsy Drug Drives Beat
09:52am, Tuesday, 02'nd Aug 2022
Harmony Biosciences crushed expectations Tuesday, citing a growing number of narcolepsy patients on its drug, and the biotech stock surged. The post Harmony Biosciences Makes Leap Out Of Buy Zone Afte
HARMONY BIOSCIENCES ANNOUNCES DATE OF SECOND QUARTER 2022 FINANCIAL RESULTS
08:05am, Tuesday, 19'th Jul 2022
PLYMOUTH MEETING, Pa. , July 19, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercial
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022
02:07pm, Wednesday, 13'th Jul 2022 Benzinga
Upgrades
For The Shyft Group Inc (NASDAQ:SHYF), DA Davidson upgraded the previous rating of Neutral to Buy. Shyft Group earned $0.06 in the first quarter, compared to $0.36 in the year-ago quarter. Th
Investors Are Paying Attention to This Pharma That Is Gaining Speed
02:15pm, Friday, 08'th Jul 2022 The Motley Fool
Can turning one product into a portfolio of products result in revenue magic?
Investors Are Paying Attention to This Pharma That Is Gaining Speed
10:15am, Friday, 08'th Jul 2022
Can turning one product into a portfolio of products result in revenue magic?
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
02:04pm, Thursday, 07'th Jul 2022 Benzinga
Upgrades
For Pacific Premier Bancorp Inc (NASDAQ:PPBI), Raymond James upgraded the previous rating of Outperform to Strong Buy. In the first quarter, Pacific Premier Bancorp showed an EPS of $0.70, co
7 No-Brainer Biotech Stocks to Add to Your Buy List
09:58am, Thursday, 09'th Jun 2022
With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. The post 7 No-Brainer Biotech Stocks to Add to Your Buy List appeared first
Harmony Biosciences: Steady Revenue Generator Looking For A Future
12:55pm, Thursday, 26'th May 2022
Harmony has done very well monetizing their first asset. They have to start planning for the future.
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2022 Earnings Call Transcript
03:30pm, Wednesday, 04'th May 2022 The Motley Fool
HRMY earnings call for the period ending March 31, 2022.
Harmony Biosciences Holdings, Inc. (HRMY) Beats Q1 Earnings Estimates
12:55pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 104% and 2.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for t
Harmony Biosciences Holdings, Inc. (HRMY) CEO John Jacobs on Q1 2022 Results - Earnings Call Transcript
12:13pm, Tuesday, 03'rd May 2022
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants Luis Sanay - Head, IR John C. Jacobs - President and CEO Jeffrey Dierks -
Harmony Biosciences Holdings, Inc. (HRMY) Beats Q1 Earnings Estimates
10:32am, Tuesday, 03'rd May 2022
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 104% and 2.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for t
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022
02:03pm, Thursday, 14'th Apr 2022 Benzinga
Upgrades
For United Parcel Service Inc (NYSE:UPS), Loop Capital upgraded the previous rating of Hold to Buy. For the fourth quarter, United Parcel Service had an EPS of $3.59, compared to year-ago qua
This group of stocks is flagging a rebound, and that's good news for the S&P 500, says technical analyst
01:05pm, Tuesday, 22'nd Mar 2022 MarketWatch
Where is the market going after last week's rally? Our call of the day from MKM's chief strategist is looking at healthy signals from the healthcare sector.
